EP1002 - ECE_3406 - Real-world BMI outcomes in adult patients with acquired hypothalamic obesity treated with setmelanotide for up to 9 months in France
Real-world evidence of 56 patients with aHO, who received up to 9 months of setmelanotide under pre-marketing early access authorization in France showed consistent improvements in BMI, underscore the real-world therapeutic value of setmelanotide as an intervention strategy for patients with aHO.